Free Trial
LON:DXRX

Diaceutics 5/13/2025 Earnings Report

Diaceutics logo
GBX 119.79 +0.79 (+0.66%)
As of 07/14/2025 11:52 AM Eastern

Diaceutics EPS Results

Actual EPS
-GBX 2.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Diaceutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Diaceutics Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Diaceutics Earnings Headlines

Royal Bank Of Canada Cuts Diaceutics (LON:DXRX) Price Target to GBX 185
I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
See More Diaceutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Diaceutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Diaceutics and other key companies, straight to your email.

About Diaceutics

At Diaceutics (LON:DXRX) we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

View Diaceutics Profile

More Earnings Resources from MarketBeat